Premium
Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children
Author(s) -
Hameed Shihab,
Ellard Sian,
Woodhead Helen J,
Neville Kristen A,
Walker Jan L,
Craig Maria E,
Armstrong Taylor,
Yu Liping,
Eisenbarth George S,
Hattersley Andrew T,
Verge Charles F
Publication year - 2011
Publication title -
pediatric diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.678
H-Index - 75
eISSN - 1399-5448
pISSN - 1399-543X
DOI - 10.1111/j.1399-5448.2010.00681.x
Subject(s) - autoantibody , medicine , diabetes mellitus , type 1 diabetes , type 2 diabetes , human leukocyte antigen , glutamate decarboxylase , insulin , endocrinology , hnf1a , insulinoma , antibody , immunology , antigen , biochemistry , enzyme , chemistry
Hameed S, Ellard S, Woodhead HJ, Neville KA, Walker JL, Craig ME, Armstrong T, Yu L, Eisenbarth GS, Hattersley AT, Verge CF. Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children. Background: Autoantibody‐negative children diagnosed with type 1 diabetes might have unrecognized monogenic or type 2 diabetes. Research design and methods: At diagnosis of type 1 diabetes (between ages 0.5 and 16.3 yr, n = 470), autoantibodies [glutamic acid decarboxylase (GAD), insulinoma‐associated protein 2 (IA2), insulin autoantibodies (IAA), and/or islet cell antibody (ICA)] were positive (ab+) in 330 and negative in 37 (unknown in 103). Autoantibody‐negative patients were retested at median diabetes duration of 3.2 yr (range 0.9−16.2) for autoantibodies (GAD, IA2, ZnT8), human leukocyte antigen (HLA) typing, non‐fasting C‐peptide, and sequencing of HNF4A, HNF1A, KCNJ11 , and INS. Results: Nineteen (5% of 367) remained persistently autoantibody negative (PAN), 17 were positive on repeat testing (PORT), and 1 refused retesting. No mutations were found in PORT. One PAN was heterozygous for P112L mutation in HNF1A and transferred from insulin to oral gliclazide. Another PAN transferred to metformin and the diagnosis was revised to type 2 diabetes. The remaining 17 PAN were indistinguishable from the ab+ group by clinical characteristics. HLA genotype was at high risk for type 1 diabetes in 82% of remaining PAN and 100% of PORT. After excluding patients with diabetes duration <1 yr, C‐peptide was detectable more frequently in the remaining PAN (7/16) and PORT (6/17) than in a random selection of ab+ (3/28, p = 0.03). Conclusions: The diagnosis of type 1 diabetes should be reevaluated in PAN patients, because a subset has monogenic or type 2 diabetes. The remaining PAN have relatively preserved C‐peptide compared with ab+, suggesting slower β‐cell destruction, but a very high frequency of diabetogenic HLA, implying that type 1B (idiopathic) diabetes is rare.